SENTINEL LYMPH NODE BIOPSY IN BREAST CANCER; OUR EXPERIENCE IN THE UNIVERSITY HOSPITAL FOR TUMORS, ZAGREB, CROATIA

DANKO VELIMIR VRDOLJAK, MLADEN STANEĆ, MIROSLAV LESAR and STJEPAN JUZBAŠIĆ
Department of Surgical Oncology, University Hospital for Tumors, Zagreb, Croatia

Summary
The study was aimed at analyzing metastatic involvement in sentinel lymph node in patients with primary breast cancer. The study includes 51 female patients undergoing surgery for primary breast cancer at the University Hospital for Tumors, Zagreb, Croatia. Prior to the standard surgical procedure, sentinel lymph node biopsy was performed and pathohistologically and immunohistochemically analyzed. Sentinel lymph node biopsy was done in 51 patients meeting the indication criteria for the procedure. In 39 (76.47%) biopsy samples immunohistochemical results were negative (no signs of metastases), in 11 (21.57%) the result was positive, and in 1 (1.96%) patient the sentinel lymph node was not located using the gamma probe following the preoperative lymphoscintigraphy.

Recently, a new phase in conserving surgery for breast cancer has started. Considering the presence of the so-called skip metastases in 2% of the cases, the idea of conserving surgery for axillary lymph nodes occurred, and thus the sentinel node surgery has been developed. In simple terms, in case the sentinel lymph node is negative, other axillary lymph nodes should not be removed; if the node is positive, a classic axillary dissection, i.e. the removal of axillary lymph nodes should be done.

KEY WORDS: breast cancer, sentinel lymph node, tumor marker CA 15-3

BIOPSIIJA LIMFNOGA ČVORA «ČUVARA» KOD RAKA DOJKE; ISKUSTVO STEČENO U KLINICI ZA TUMORE, ZAGREB, HRVATSKA

Sažetak
U radu je analizirana metastatska zahvaćenost limfnoga čvora «čuvara» u bolesnica s primarnim rakom rojke. Analizirana je 51 bolesnica s primarnim rakom dojke operirana u Klinici za tumore, Zagreb, Hrvatska u razdoblju. Prije standardnog kirurškog zahvata, učinjena je biopsija čimfnog čvora «čuvara», a potom su uzorci analizirani patohistološki i imunohistokemijski.

Bioptija limfnog čvora stražara je učinjena u 51 bolesnica koje su zadovoljavale indikaciju za navedeni postupak. U 39 (76,47%) uzoraka biopsije imunohistokemijska obrada dala negativan rezultat (nema znakova metastaza), u 11 (21,57%) uzoraka je nalaz pozitivan, a u jedne (1,96%) bolesnice limfnī čvor "stražar" nije lociran gama-kamerom nakon preoperacijske limfoscintigrafije.

U zadnje vrijeme teži se poštivanim zahvatima u postupcima operacije raka dojke. Znajući da je postojanje tzv. "skip metastaza" negdje oko 2 %, pojavljuje se ideja o poštivnoj operaciji aksilarnih limfnih čvorova. Tako je stvorena kirugija "sentinel" limfnog čvora (limfnog čvora "stražara"). Pojednostavljeno, ako je "sentinel" limfnī čvor negativan, ne bi trebalo uklanjati druge limfnie čvorove u pazuhu, a ako je pozitivan, činila bi se i dalje klasična disekcija aksile s uklanjanjem aksilarnih limfnih čvorova.

KLJUČNE RIJEČI: rak dojke, limfnī čvor "čuvar", tumorski biljeg CA 15-3
INTRODUCTION

The axillary lymph node status is among the most important information gained from surgery, regarding both the prognosis and further treatment. There are three anatomic levels of axillary lymph nodes, and routine surgical procedures usually involve removal of all lymph nodes. Recently, intraoperative sentinel lymph node biopsy has been used to avoid the unnecessary removal of healthy axillary nodes. Actually, numerous studies show that the lymphatic spread of cancer occurs through the first lymph node of the associated nodal basin - the so-called sentinel lymph node, and that metastatic skipping of the mentioned node (the so-called «skip metastases») is a very rare occurrence, developing in less than 2% of breast-cancer cases. Knowledge of the sentinel lymph node and its identification helps avoid the unnecessary dissection of uninvolved axillary lymph nodes, and reduce additional patient morbidity. The routine procedure will therefore include the lymph node removal only in case of the positive sentinel lymph node.

The study includes:
1. The presence of metastatic changes in the sentinel lymph node with the following indication: tumor not exceeding 3 cm, clinically negative axillary lymph nodes, no signs of breast tumor multicentricity, no previous operations or irradiation of the axilla.

PATIENTS AND METHODS

The study includes 51 female patients undergoing surgery for primary breast cancer at the University Hospital for Tumors, Zagreb, Croatia. Prior to the standard surgical procedure (segmentectomy or mastectomy with axillary dissection), sentinel lymph node biopsy was performed and pathohistologically and immunohistochemically analyzed.

The indication for sentinel node biopsy in breast cancer is as follows: a maximal tumor diameter not exceeding 3 cm, clinically negative axillary lymph nodes, no previous operations or axillary irradiation. Following the indication, the patients underwent preoperative lymphoscintigraphy at the Department of Nuclear Medicine. Using colloid Te⁹⁹ solution, the regional lymphatic drainage area in primary tumor was determined, and the position of the sentinel lymph node marked; the sentinel node biopsy procedure should be done within 12 hours following the lymphoscintigraphy. The node is detected intraoperatively using a dual method: a) preoperative intracutaneous injection of 2 ml lymphazurin (blue dye) in the area surrounding the primary tumor, and b) intraoperative mapping with the ã-probe. The sentinel lymph node is stained by the blue dye, and the γ-probe provides the highest numeric and auditory response to Te⁹⁹. If the γ-probe did not provide signals of radioactivity, or if it showed minimum radioactivity at the site of a removed node, the node was considered a sentinel lymph node. The removed sentinel node was then further analyzed histochemically and immunohistochemically (Figures 1, 2, 3).

Immunohistochemical staining of lymph node metastases was performed using the PAP method and the equipment of TECH MATE™ HORIZON AUTOMATED IMMUNOSTEINER (Denmark), DAKO (Denmark) monoclonal antibodies – cytokeratine No M821, low-molecular-weight cytokeratine 8 No M631 and high-molecular-weight cytokeratine No M630.

Figure 1. Increased auditory signal intensity during identification of the sentinel lymph node.
RESULTS

Sentinel lymph node biopsy was done in 51 patients meeting the indication for the procedure, and all sentinel lymph nodes were immunohistochemically analyzed. Table 1 shows immunohistochemical findings which in 39 (76.47%) biopsy samples were negative (no signs of metastases), in 11 (21.57%) samples it was positive, and in one (1.96%) patient the sentinel lymph node was not located with the gamma camera following preoperative lymphoscintigraphy (Table 1). In patients with sentinel node-negative findings, metastatic foci were found in none (0%) of the remaining axillary lymph nodes.

DISCUSSION

The progress of medicine, screening programs, raising consciousness on issues related to breast cancer, clinical examinations, mammography and US scanning, work together to contribute that the size of newly detected tumors is increasingly smaller. In smaller breast cancers, 70-80% of axillary lymph nodes are negative for malignancy. Although the axillary lymph nodes are the best indicator of the stage of the disease, in 70-80% of breast cancer patients their removal may be unnecessary as well as its associated morbidity (1-4).

Sentinel lymph node biopsy (SLNB) has been developed over 20 years. In 1977, Holmes et al. reported on a melanoma patient in whom radioactive gold colloid was used as a tracer of the regional lymph-node basin. Parallelly, Cabanas used the procedure in a patient with penile carcinoma to trace the involved regional lymphatic field and introduced the term of sentinel node as the first lymph node that the regional lymph ducts drain into (5, 6).

Giuliano was the first to use a «patent blue» dye (lymphazurine) injecting it into the area surrounding the tumor, similar to the above case of melanoma (7, 8). Krag was among the first to in-
roduce lymphoscintigraphic mapping of the sentinel lymph node in breast cancer patients, with preoperative injecting radiocolloid Te⁹⁹ into the tumor coupled with the intraoperative use of a radiosensitive probe (gamma-probe) (9). Many studies were published providing justification for the technique. In the studies, either the blue dye or radioisotope technique, and, occasionally, the combination of both were used, which proved to be the most reliable approach (10). Unreliable criteria for the sentinel lymph, and thus contraindications to this approach include (11-13):

1. positive axillary lymph nodes
2. tumor multicentricity
3. primary tumor size exceeding 3 cm

In time, the surgical technique known as sentinel lymph node biopsy has evolved and become the standard method for axillary staging in breast cancer patients with smaller tumors while avoiding routine axillary dissections (13-17).

Pathohistological analysis is a challenging problem in the sentinel lymph node surgery. Actually, routine intraoperative diagnostics with standard hematoxilin and eosin (H&E) staining of frozen sections requires an experienced pathologist and is time-consuming. This histological examination had to be complemented by immunohistochemical examination. Veronesi et al. reported 32.1% of false-negative results obtained by traditional H&E staining, while the immunohistochemical method achieved accuracy of over 98% (14, 18-20).

Past studies suggest the necessity for removal of the sentinel lymph node after breast surgery. Following immunohistochemical evaluation, a second surgical procedure still includes standard removal of the axillary lymph nodes in case of immunohistochemical-positive sentinel lymph nodes (with metastatic changes); in case of negative immunohistochemical findings, however, additional mutilation of the axilla and its associated morbidity is considered unnecessary.

The above mentioned, of course, stands if the sentinel lymph node is among the axillary lymph nodes. A large portion of breast cancers do not have the lymphatic drainage into the axillary lymph nodes as the first nodes within the the area of lymphatic drainage basin. Uren substantiated that some of lymphatic drainage goes into the lymph nodes of the internal mammary artery, some into the supraclavicular lymph node, and some into the interpectoral (Rotter’s), subclavicular and intramammary lymph nodes. These nodes can also be sentinel lymph nodes. However, they are, inaccessible by the above techniques, so, for the time being, the sentinel lymph node surgery is applicable only when the sentinel node is located in the axillary lymph nodes (21).

Besides all the above, the procedure requires a well experienced team of surgeons and pathologists; the European School of Oncology would not recommend tackling this problem unless by a surgeon or a pathologist who does at least fifty-odd such procedures per year (14, 17, 18).

CONCLUSION

Recently, a new phase in conserving surgery for breast cancer has started. Considering the presence of the so-called skip metastases in 2% of the cases, the idea of conserving surgery for axillary lymph nodes occurred. Thus, the sentinel lymph node surgery has been developed. In simple terms, in case of a negative sentinel lymph node, other lymph nodes in the axilla should not be removed; if the node is positive, a classic axillary dissection, i.e. the removal of axillary lymph nodes should be done.

Sentinel lymph nodes are identified by immunohistochemistry providing superior accuracy of the diagnosis.

Based on the study of 51 breast cancer patients with a reasonable indication for the sentinel lymph node biopsy, the sentinel node was found in 98% of the patients. The node was negative in 39 (76.5%) of the studied patients. In all of the sentinel node negative patients, other axillary lymph nodes were also negative for the presence of metastases.

REFERENCES


Received for publication: December 23, 2003

Author’s address: Danko Velimir Vrdoljak, M.D., Department OF Surgical Oncology, University Hospital for Tumors, Illica 197, 10 000 Zagreb, Croatia; E-mail: d.v.vrdoljak@kzt.hr